[Form 4] Esperion Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Esperion Therapeutics insider transaction: Benjamin Looker, listed as General Counsel and an officer, reported a sale of 6,267 shares of Esperion Therapeutics common stock on 09/17/2025 at a reported price of $2.804 per share. The filing states the shares were sold to satisfy tax obligations on vested restricted stock units. After the sale, Mr. Looker is reported to beneficially own 393,670 shares, held directly. The Form 4 was signed by a power of attorney on 09/18/2025. The report contains no other derivative transactions or additional explanatory disclosures.

Positive

• Clear disclosure of the transaction date, price, and reason for sale (tax withholding on vested RSUs)
• Beneficial ownership shown after the sale (393,670 shares), providing transparency

Negative

• None.

Insights

Securities Analyst

TL;DR: An officer sale to cover taxes; transaction size appears routine relative to ongoing equity compensation.

The 6,267-share sale at $2.804 per share is explicitly described as a tax-withholding disposition of vested restricted stock units. The filing reports direct beneficial ownership of 393,670 shares after the sale. There is no indication of derivative activity, additional sales, or purchases in this Form 4. The signature is executed by an attorney-in-fact, which is common for timely filings. Based solely on the disclosed facts, this is a routine insider tax-related sale rather than an unusual trading pattern.

Corporate Governance Expert

TL;DR: Officer disclosed routine withholding sale; governance practices appear followed based on the filing.

The report identifies the reporting person as General Counsel and indicates the shares sold were to satisfy tax obligations tied to vesting events. The Form 4 shows direct ownership and includes the required signature via power of attorney dated 09/18/2025. There are no notes of extraordinary transactions, stock pledges, or change in control events. From a compliance perspective, the filing contains the essential elements and a clear explanation for the disposition.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Looker Benjamin

(Last) (First) (Middle)

C/O ESPERION THERAPEUTICS, INC.

3891 RANCHERO DRIVE, SUITE 150

(Street)

ANN ARBOR MI 48108

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Esperion Therapeutics, Inc. [ ESPR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
09/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/17/2025		S		6,267(1)	D	$2.804	393,670	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares were sold to satisfy tax obligation on vested shares of restricted stock units.

Remarks:

	/s/ Sheldon L. Koenig, by power of attorney	09/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Benjamin Looker report in the Form 4 for ESPR?

He reported a sale of 6,267 shares on 09/17/2025 at $2.804 per share to satisfy tax obligations on vested restricted stock units.

How many ESPR shares does the reporting person own after the transaction?

The Form 4 states the reporting person beneficially owns 393,670 shares following the reported sale.

Was the sale part of an option or RSU event according to the filing?

Yes; the filing explicitly says the shares were sold to satisfy tax obligations on vested restricted stock units.

Who signed the Form 4 for this ESPR filing?

The filing is signed by Sheldon L. Koenig by power of attorney on 09/18/2025.